Patents Assigned to AstraZeneca
  • Compound
    Patent number: 8735413
    Abstract: There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: May 27, 2014
    Assignee: AstraZeneca AB
    Inventors: Stephen Connolly, Mark Richard Ebden, Iain Alastair Stewart Walters, Thomas Langer, Alan Robert Steven, Craig Robert Stewart, Paula Margaret Tomlin, Andrew John Williams
  • PEPTIDE YY AND PEPTIDE YY AGONISTS FOR TREATMENT OF METABOLIC DISORDERS
    Publication number: 20140135261
    Abstract: Methods and compositions are disclosed to treat metabolic disorders such as obesity, diabetes, and increased cardiovascular risk comprising administering a therapeutically effective amount of a PYY or a PYY agonist.
    Type: Application
    Filed: January 24, 2014
    Publication date: May 15, 2014
    Applicants: ASTRAZENECA PHARMACEUTICALS LP, AMYLIN PHARMACEUTICALS, LLC
    Inventors: Richard A. PITTNER, Andrew A. YOUNG, James R. PATERNITI
  • Process for the Preparation of Benzyl [(3aS,4R,6S,6aR)-6-hydroxy-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol]-4-yl]carbamate and Intermediates in the Process
    Publication number: 20140135509
    Abstract: The present invention is directed to a process for the preparation of benzyl [(3aS,4R,6S,6aR)-6-hydroxy-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]carbamate (VI), to products of said process and the use thereof.
    Type: Application
    Filed: May 11, 2012
    Publication date: May 15, 2014
    Applicant: ASTRAZENECA AB
    Inventor: Tibor Musil
  • Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
    Patent number: 8722741
    Abstract: The invention relates to substituted phenoxyacetic acids of formula (I), where the variables are as defined in claim 1, as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: May 13, 2014
    Assignee: AstraZeneca AB
    Inventors: Timothy Jon Luker, Timothy Nicholas Birkinshaw, Rukhsana Tasneem Mohammed
  • Pyrimidine sulphonamide derivatives as chemokine receptor modulators
    Patent number: 8722883
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 13, 2014
    Assignee: AstraZeneca AB
    Inventors: David Ranulf Cheshire, Rhona Jane Cox, Premji Meghani, Cherylin Francis Preston, Jeffrey Paul Stonehouse, Neal Michael Smith
  • CHEMICAL COMPOUNDS 542
    Publication number: 20140128371
    Abstract: The present invention relates to compounds of Formula (I): to pharmaceutically acceptable salts thereof, to methods of using them to treat bacterial infections, and to methods for their preparation.
    Type: Application
    Filed: January 13, 2014
    Publication date: May 8, 2014
    Applicant: ASTRAZENECA AB
    Inventors: Kevin BARVIAN, Gregory Steven BASARAB, Madhusudhan Reddy GOWRAVARAM, Sheila Irene HAUCK, Fei ZHOU
  • Quinazoline Derivatives as VEGF Inhibitors
    Publication number: 20140121228
    Abstract: The invention relates to quinazoline derivatives of formula (I), wherein m is an integer from 1 to 3; R1 represents halogeno or C1-3alkyl; X1 represents —O—; R2 is selected from one of the following three groups: 1) C1-5alkylR3, wherein R3 is piperidinyl-4-yl which may bear one or two substituents selected from hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl and C1-4alkoxy; 2) C2-5alkenylR3, wherein R3 is as defined herein; 3) C2-5alkynylR3, wherein R3 is as defined herein; and wherein any alkyl, alkenyl or alkynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof; processes for their preparation; pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Application
    Filed: January 3, 2014
    Publication date: May 1, 2014
    Applicant: ASTRAZENECA AB
    Inventors: Andrew Peter Thomas, Elaine Sophie Elizabeth Stokes, Laurent Francois Andre Hennequin
  • THERAPEUTIC TREATMENT
    Publication number: 20140121227
    Abstract: The present invention relates to a combination comprising (5)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide, or a pharmaceutically acceptable salt thereof, hereafter “Compound (I)”, and a taxane. Taxanes include established cancer drugs such as docetaxel (Taxotere™) and paclitaxel (Taxol™). Such combinations may be useful in the treatment or prophylaxis of cancer. The invention also relates to a pharmaceutical composition comprising such Compound (I) and a taxane. The invention further relates to a method of treatment comprising the simultaneous, sequential or separate administration of Compound (I) and a taxane, to warm-blooded animal, such as man. The invention also relates to a kit comprising Compound (I) and a taxane, optionally with instructions for use.
    Type: Application
    Filed: April 2, 2012
    Publication date: May 1, 2014
    Applicant: AstraZeneca AB
    Inventor: Barry Robert Davies
  • Heterocyclic compounds as CCR2B antagonists
    Patent number: 8710224
    Abstract: Compounds of formula (I) Q-L-W—C(?X)—Z—P wherein Q is an amine of the formula —N(R1)(R2); L is an alkyl or heterocyclyl-alkyl linker; W is a 6- or 7-membered aliphatic ring comprising ring atoms Y1 and Y2 which are linked to groups L and C(X) respectively and Y1 and Y2 are independently selected from N and C; X is O, N, N—CN or S; Z is NR3; P is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group; and pharmaceutically acceptable salts or solvates thereof, are useful in the treatment of C—C chemokine mediated conditions.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: April 29, 2014
    Assignee: AstraZeneca AB
    Inventors: Justin Fairfield Bower, Jeffrey Philip Poyser, Paul Turner, David Waterson, Jon James Gordon Winter
  • ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION
    Publication number: 20140107019
    Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, short bowel syndrome, Parkinson's disease, cardiovascular disease, and other and disorders of the central nervous system.
    Type: Application
    Filed: March 28, 2013
    Publication date: April 17, 2014
    Applicants: ASTRAZENECA PHARMACEUTICALS LP, AMYLIN PHARMACEUTICALS, LLC
    Inventors: Amylin Pharmaceuticals, LLC, Astrazeneca Pharmaceuticals LP
  • Compounds useful for the synthesis of S- and R-omeprazole and a process for their preparation
    Patent number: 8697880
    Abstract: The present invention relates to an improved method for the synthesis of the (S)- or (R)-enantiomer of omeprazole, characterized in that 2-[[(4-X-3,5-dimethylpyridin-2-yl)methyl]thio]-5-methoxy-1H-benzimidazole or 2-[[(4-X-3,5-dimethyl-1-oxidopyridin-2-yl)methyl]thio]-5-methoxy-1H-benzimidazole, wherein X is a leaving group, is oxidized into the corresponding sulphoxide which is obtained as a crystalline compound. Recrystallization of the thus obtained sulphoxide results in a compound of enhanced chemical and optical purity, which is subsequently transformed into the (S)- or (R)-enantiomer of omeprazole.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: April 15, 2014
    Assignee: AstraZeneca AB
    Inventors: Sverker Von Unge, Christina Fregler
  • ENTRAINING POWDER IN AN AIRFLOW
    Publication number: 20140096771
    Abstract: A device for inhalation of at least one air stream carrying a dose of medicament powder. The device comprises a powder-containing cavity which opens into a flow passage. The flow passage is arranged to direct an inhalation air flow across the cavity opening. A circulating flow is thereby induced in the cavity by the phenomenon of shear driven cavity flow. Powder is entrained in the circulating flow and deaggregated before exiting the cavity and becoming entrained in the flow of air along the flow passage.
    Type: Application
    Filed: October 11, 2013
    Publication date: April 10, 2014
    Applicant: AstraZeneca AB
    Inventors: Johan REMMELGAS, Per Arne KJELLGREN, Orest LASTOW, Mårten SVENSSON
  • Therapeutic agents
    Patent number: 8685958
    Abstract: Disclosed herein are azetidinyl compounds of formula I, as described herein, pharmaceutical compositions comprising an azetidinyl compound, and a method of using an azetidinyl compound in the treatment or prophylaxis of a melanin-concentrating hormone related disease or condition.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: April 1, 2014
    Assignee: AstraZeneca AB
    Inventor: Lars Anders Mikael Johansson
  • Combination product comprising SRC kinase inhibitor AZDO530 and an antioestrogen or EGFR-TK-inhibitor
    Patent number: 8680109
    Abstract: The invention relates to a combination for use in the synergistic treatment of breast cancer comprising an antioestrogen and the Src kinase inhibitor AZD0530, a combination for the synergistic treatment of cancer comprising an EGFR TKI and the Src kinase inhibitor AZD0530 and a triple combination for the synergistic treatment of breast cancer comprising an antioestrogen, an EGFR TKI and the Src kinase inhibitor AZD0530.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: March 25, 2014
    Assignee: AstraZeneca AB
    Inventor: Tim Paul Green
  • Pharmaceutical Formulations Including An Amine Compound
    Publication number: 20140079778
    Abstract: The present invention relates to solid, semisolid, or liquid formulations comprising water soluble antioxidants that prevent or reduce formic acid and/or formyl species generation in the dosage form during the manufacturing process and/or during shelf-life storage. The formulations of the present invention prevent or reduce formation of N-formyl impurities (and gelatin crosslinking) during the manufacturing process and/or during shelf-life storage.
    Type: Application
    Filed: January 31, 2012
    Publication date: March 20, 2014
    Applicants: AstraZeneca UK Limited, Bristol-Myers Squibb Company
    Inventors: Ajit Narang, Venkatramana M. Rao, Divyakant S. Desai
  • Chromenone derivatives
    Patent number: 8673906
    Abstract: The invention concerns chromenone derivatives of Formula I or a pharmaceutically-acceptable salts thereof, wherein each of R1, R2, R3, R4, R5, R6, R7, R8, n and R9 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: March 18, 2014
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Sebastien Louis Degeorge, Christine Marie Paul Lambert-Van Der Brempt, Remy Robert Morgentin, Patrick Ple
  • Pharmaceutically acceptable salts of methyl (3-{ [[3-(6-amino- 2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl) propyl] (3-morpholin-4-ylpropyl) amino] methyl }phenyl) acetate and their use in therapy
    Patent number: 8673907
    Abstract: The present invention concerns hydrochloric acid, hydrobromic acid and maleic acid salts of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate, compositions comprising them and their use in therapy.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: March 18, 2014
    Assignees: AstraZeneca AB, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Thomas McInally, Håkan Schulz
  • Chemical compounds
    Patent number: 8673938
    Abstract: Compounds of formula (I): wherein variable groups are defined within; their use in the inhibition of 11?HSD1, processes for making them and pharmaceutical compositions comprising them are described.
    Type: Grant
    Filed: August 14, 2009
    Date of Patent: March 18, 2014
    Assignee: AstraZeneca AB
    Inventors: William McCoull, Martin Packer, James Stewart Scott, Paul Robert Owen Whittamore
  • Methods For Affecting Body Composition
    Publication number: 20140066368
    Abstract: Methods for affecting body composition include the use of amylin or amylin agonist(s). Total body weight be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased.
    Type: Application
    Filed: August 20, 2013
    Publication date: March 6, 2014
    Applicants: AstraZeneca Pharmaceuticals, LP, Amylin Pharmaceuticals, LLC
    Inventors: Christine Marie Mack, Jonathan David Roth
  • Dental implant
    Patent number: RE44800
    Abstract: Dental implant (10) for rotation into the bone tissue of a jaw bone consisting of a body having an axis of rotation, a coronal end surface (5), an apical end surface (1) and a generally cylindrical section (7) which has a coronal edge coincident with, or in close proximity to, the coronal end surface and an outer peripheral surface which extends apically towards the apical end surface from the coronal edge. The outer peripheral surface is presented by a circumferentially-oriented roughness (19) comprising a series of circumferentially-oriented peaks which are axially spaced apart by troughs and oriented at an inclined angle to the axis of rotation. The height from the troughs to the peaks throughout the circumferentially-oriented roughness is greater than 0.2 mm.
    Type: Grant
    Filed: April 24, 2003
    Date of Patent: March 11, 2014
    Assignee: Astrazeneca AB
    Inventor: Stig Hansson